Gloria Echeverria Lab

Publications

Master
Content

Laboratory models to study breast cancer therapy resistance and metastasis. Roarty KP, Echeverria GV. Front Oncol. 2021 March 10. Doi: 10.3389/fonc.2021.645698.

Methodological advancements for investigating intra-tumoral heterogeneity in breast cancer at the bench and bedside. Baek M, Chang JT, Echeverria GV. J Mammary Gland Biol Neoplasia. 2020 Dec 9. Doi: 10.1007/s10911-020-09470-3.

Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. Powell RT, Redwood A, Liu X, Gui L, Cai S, Zhou X, Tu Y, Qi Y, Jiang Y, Echeverria GV, Feng N, Ma X, Giuliani V, Marzalek JR, Heffernan TP, Vellano CR, Stephan C, Davies P, Chang JT, Moulder SL, Symmans WF, Piwnica-Worms H. Scientific Reports. Oct 21;10(1):17899. doi: 10.1038/s41598-020-74882-4.

Resistance to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Mediated By A Reversible Drug-Tolerant State. Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, McCoy A, Cai S, Tu Y, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, Shao J, Ma X, Harris A, Mundi P, Lau R, Ramamoorthy V, Qu Y, Alvarez M, Califano A, Moulder S, Symmans W, Marszalek J, Heffernan T, Chang JT, Piwnica-Worms H. Science Translational Medicine. 2019 Apr 17. 11:488. Doi: 10.1126/scitranslmed.aav0936.

High-Resolution Clonal Mapping of Multi-Organ Metastasis in Triple Negative Breast Cancer. Echeverria GV*, Powell E*, Seth S*, Ge Z, Carugo A, Bristow C, Peoples M, Robinson F, Shao J, Zhang X, Cai S, Wu W, Draetta G, Symmans F, Moulder S, Chang JT, Heffernan T#, Piwnica-Worms H#. Nature Communications. 2018 Nov 29. 9:5079. Doi: 10.1038/s41467-018-07406-4.

Phosphorylation of Serine 367 of FOXC2 by P38 Regulates ZEB1 and Breast Cancer Metastasis.  Werden SJ, Sphyris N, Sarkar TR, Paranjape AN, LaBaff AM, Tabue JH, Hollier BG, Ramirez-Pena EQ, Soundarajan R, den Hollander P, Powell E, Echeverria GV, Miura N, Chang JT, Piwnica-Worms H, Rosen JM, Mani SA. Oncogene. 2016 Jun 13; doi: 10.1038/onc.2016.203.

Metastatic Potential by Promoting Tumor Growth in Primary and Metastatic Sites in PDX Models of Triple Negative Breast Cancer.  Powell E, Shao J, Yuan Y, Chen H, Cai S, Echeverria GV, Mistry N, Decker K, Schlosberg C, Do K, Edwards J, Liang H, Piwnica-Worms D, Piwnica-Worms H. Breast Cancer Research. 2016Jan 27;18(1):13. Doi:10.1186/s13058-016-0673-9.

p53 deficiency linked to BTG2 loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in PDX models of triple negative breast cancer. Powell E, Shao J, Yuan Y, Chen H, Cai S, Echeverria GV, Mistry N, Decker K, Schlosberg C, Do K, Edwards J, Liang H, Piwnica-Worms D, Piwnica-Worms H. Breast Cancer Research. 2016Jan 27;18(1):13. Doi:10.1186/s13058-016-0673-9.

The Spliceosome is a Therapeutic Vulnerability in MYC-Driven Cancer. Hsu T, Simon L, Heill N, Marcotte R, Sayad A, Bland C, Echeverria GV, Sun T, Kurley S, Tyagi S, Karlin K, Dominguez-Vidana R, Hartman J, Renwick A, Scorsone K, Bernardi R, Skinner S, Jain A, Orellana M, Lagisetti C, Golding I, Jun S, Neilson J, Zhang X, Cooper TA, Webb T, Neel B, Shaw CA, Westbrook TF. Nature. 2015 Sep 17;525(7569): 384-8. Doi: 10.1038/nature14985.